19 Einträge gefunden

1. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials

   1. Bieber, T
   2. Thyssen, J P
   3. Reich, K
   4. Simpson, E L
   5. Katoh, N
   6. Torrelo, A
   7. De Bruin-Weller, M

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
2. Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method

   1. Mrowietz, U
   2. Warren, R B
   3. Leonardi, C L
   4. Saure, D
   5. Petto, H
   6. Hartz, S
   7. Dossenbach, M

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2

   1. Reich, K
   2. Gordon, K B
   3. Strober, B E
   4. Armstrong, A W
   5. Miller, M
   6. Shen, Y K
   7. You, Y

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
4. Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2)

   1. Gordon, K B
   2. Warren, R B
   3. Gottlieb, A B
   4. Blauvelt, A
   5. Thaçi, D
   6. Leonardi, C
   7. Poulin, Y

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
5. The value of subcutaneous vs. oral methotrexate: real-world data from the German psoriasis registry PsoBest

   1. Reich, K
   2. Sorbe, C
   3. Griese, L
   4. Reich, J L K
   5. Augustin, M

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
6. Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study

   1. Reich, K
   2. Körber, A
   3. Mrowietz, U
   4. Sticherling, M
   5. Sieder, C
   6. Früh, J
   7. Bachhuber, T

   2021 - Forschungsinformationssystem des UKE
7. Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3

   1. Warren, R B
   2. Hansen, J B
   3. Reich, K
   4. Paul, C
   5. Puig, L

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
8. Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis

   1. Reich, K
   2. Mrowietz, U
   3. Menter, A
   4. Griffiths, C E M
   5. Bagel, J
   6. Strober, B
   7. Nunez Gomez, N

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
9. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study

   1. Reich, K
   2. Sullivan, J
   3. Arenberger, P
   4. Jazayeri, S
   5. Mrowietz, U
   6. Augustin, M
   7. Elewski, B

   2021 - Forschungsinformationssystem des UKE
10. A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS)

    1. Wilsmann-Theis, D
    2. Kromer, C
    3. Gerdes, S
    4. Linker, C
    5. Magnolo, N
    6. Sabat, R
    7. Reich, K

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
11. Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach

    1. Tsakok, T
    2. Rispens, T
    3. Spuls, P
    4. Nast, A
    5. Smith, C
    6. Reich, K

    2021 - Forschungsinformationssystem des UKE
12. Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment

    1. Leutz, A
    2. Pinter, A
    3. Thaçi, D
    4. Augustin, M
    5. Schuster, C
    6. Fotiou, K
    7. Hundemer, H P

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
13. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies

    1. Blauvelt, A
    2. Paul, C
    3. van de Kerkhof, P
    4. Warren, R B
    5. Gottlieb, A B
    6. Langley, R G
    7. Brock, F

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
14. A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)

    1. Pinter, A
    2. Hoffmann, M
    3. Reich, K
    4. Augustin, M
    5. Kaplan, K
    6. Gudjónsdóttir, S D
    7. Delvin, T

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
15. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study

    1. Gottlieb, A B
    2. Merola, J F
    3. Reich, K
    4. Behrens, F
    5. Nash, P
    6. Griffiths, C E M
    7. Bao, W

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
16. Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial

    1. Warren, R B
    2. Carrascosa, J M
    3. Fumero, E
    4. Schoenenberger, A
    5. Lebwohl, M G
    6. Szepietowski, J C
    7. Reich, K

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
17. Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3

    1. Reich, K
    2. Hansen, J B
    3. Puig, L
    4. Konstantinou, M P
    5. Warren, R B

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
18. Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study

    1. Maul, J-T
    2. Augustin, M
    3. Sorbe, C
    4. Conrad, C
    5. Anzengruber, F
    6. Mrowietz, U
    7. Reich, K

    2021 - Forschungsinformationssystem des UKE
19. Network meta-analyses in psoriasis: overview and critical discussion

    1. Augustin, M
    2. Valencia López, Maria José
    3. Reich, K

    2021 - Forschungsinformationssystem des UKE - frei zugänglich